Article
Vandetanib inhibits both VEGFR-2 and EGFR signalling at clinically relevant drug levels in preclinical models of human cancer.
International journal of oncology - 1 Jul 2011
Brave Sandra R, Odedra Rajesh, James Neil H, Smith Neil R, Marshall Gayle B, Acheson Kerry L, Baker Dawn, Howard Zoe, Jackson Lynsay, Ratcliffe Kirsty, Wainwright Anna, Lovick Susan C, Hickinson D Mark, Wilkinson Robert W, Barry Simon T, Speake Georgina, Ryan Anderson J
Abstract excerpt
Vandetanib is a multi-targeted receptor tyrosine kinase inhibitor that is in clinical development for the treatment of solid tumours. This preclinical study examined the inhibition of two key signalling pathways (VEGFR-2, EGFR) at drug concentrations similar to those achieved in the clinic, and their contribution to direct and indirect antitumour effects of vandetanib. For in vitro studies, receptor...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.